Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Literature DB >> 9832270

In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

E J Giamarellos-Bourboulis¹, H Sambatakou, P Grecka, H Giamarellou.

Abstract

In a study designed to obtain data on compounds active against enterococci, the minimum inhibitory concentrations (MICs) of quinupristin/dalfopristin (RP 59500) and the novel quinolones DU-6859a, trovafloxacin, levofloxacin, and sparfloxacin were determined for 122 Enterococcus faecalis and seven Enterococcus faecium isolates. In addition, 15 Enterococcus faecalis isolates resistant to gentamicin, DU-6859a, and trovafloxacin were exposed over time to combinations of DU-6859a plus gentamicin and trovafloxacin plus gentamicin. DU-6859a and trovafloxacin were found to be the most active compounds against Enterococcus faecalis and DU-6859a and RP 59500 against Enterococcus faecium. Synergy between either DU-6859a or trovafloxacin and gentamicin was observed with 27 to 35% of the isolates. It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin.

Entities: Chemical Species

Mesh：

Substances：

Year: 1998 PMID： 9832270 DOI： 10.1007/bf01708351

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

13 in total

1. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors: M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal: Antimicrob Agents Chemother Date: 1995-01 Impact factor: 5.191

2. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors: R Wise; D Mortiboy; J Child; J M Andrews
Journal: Antimicrob Agents Chemother Date: 1996-01 Impact factor: 5.191

Review 3. Quinupristin-dalfopristin.

Authors: H M Bryson; C M Spencer
Journal: Drugs Date: 1996-09 Impact factor: 9.546

4. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.

Authors: V Korten; J F Tomayko; B E Murray
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

5. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors: G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

6. Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci.

Authors: V Korten; I Erdem; B E Murray
Journal: Diagn Microbiol Infect Dis Date: 1996-10 Impact factor: 2.803

7. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors: B B Gooding; R N Jones
Journal: Antimicrob Agents Chemother Date: 1993-02 Impact factor: 5.191

8. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.

Authors: R N Jones; D M Johnson; D J Biedenbach; S A Marshall
Journal: Diagn Microbiol Infect Dis Date: 1995-11 Impact factor: 2.803

Review 2. The future of the quinolones.

Authors: V T Andriole
Journal: Drugs Date: 1999 Impact factor: 9.546

2 in total